Back

ImmuneOncia surges 29.94% after IND amendment approval

Verifying
  • ImmuneOncia added a PDAC cohort to its IMC-002 Phase 1b clinical trial.
  • 29.94%: ImmuneOncia rose to 3,515 Korean won, up 810 won, at 9:12 a.m.
  • ImmuneOncia announced Ministry approval on the 4th of last month.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.